* INEGY (ezetimibe/simvastatin) 10 mg/20 mg 14 Tablets.
* Indications:
– Primary Hypercholesterolemia:
INEGY is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density
lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), & non-high-density lipoprotein cholesterol
(non-HDL-C), & to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial &
non-familial) hypercholesterolemia or mixed hyperlipidemia.
– Homozygous Familial Hypercholesterolemia (HoFH):
INEGY is indicated for the reduction of elevated total-C levels in patients with HoFH. Patients may also receive
adjunctive treatments (e.g. LDL apheresis).
* Dosage & Administration:
– The patient should be placed on a standard cholesterol-lowering diet before receiving INEGY & should continue on this diet
treatment with INEGY.
– The dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, & response.
– INEGY should be taken as a single daily dose in the evening, with or without food.
– The dosage range is 10/10 mg/day through 10/80 mg/day. The recommended usual starting dose is 10/20 mg/day.
Initiation of therapy with 10/10 mg/day may be considered for patients requiring less aggressive LDL-C reductions.
Patients who require a larger reduction in LDL-C (greater than 55%) may be started at 10/40 mg/day.
After initiation or titration of INEGY, Lipid levels may be analyzed after 2 or more weeks & dosage adjusted, if needed.
– Dosage in Patients with Homozygous Familial Hypercholesterolemia: The recommended dosage is INEGY 10/40 mg/day
or 10/80 mg/day in the evening. INEGY should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis)
in these patients or if such treatments are unavailable.
– Use in the elderly: No dosage adjustment is required for elderly patients.
* Contraindications:
– Hypersensitivity to the active substances or to any of the excipients.
– Active liver disease or unexplained persistent elevations of serum transaminases.
– Pregnancy and nursing.
* Precautions:
Myopathy / Rhabdomylosis:
– Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy, Rhabdomylosis
mainfested as muscle pain, tenderness or weakness with creatine kinase (CK) above 10X the upper limit
of normal (ULN).
– The risk of myopathy / rhabdomylosis is increased by concomitant use of INEGY with the following:
Potent inhibitors of CYP3A4, e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin,
HIV protease inhibitors, or nefazodone, particularly with higher doses of INEGY.
* Store at Temperature not exceeding 30 degrees C. Store in the original package in order to protect from moisture and light.
* Manufactured by: MSD Technology / Singapore – Singapore.
Packed by: Global Napi Pharmaceuticals (GNP) – Egypt.
For: MSD – SP Limited – U.K.
For: Merck Sharp & Dohme, Haarlem – Netherlands. (Schering-Plough).
Trademark (TM) of MSD.
Weight | 100 kg |
---|
Q & A
Ask a question
Your question will be answered by a store representative or other customers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the question!
Your question has been received and will be answered soon. Please do not submit the same question again.
Error
An error occurred when saving your question. Please report it to the website administrator. Additional information:
Add an answer
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Thank you for the answer!
Your answer has been received and will be published soon. Please do not submit the same answer again.
Error
An error occurred when saving your answer. Please report it to the website administrator. Additional information:
Reviews
There are no reviews yet